- Home
- VBF vs MDWD Comparison
VBF vs MDWD Comparison
Compare VBF & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VBF
- MDWD
- Stock Information
- Founded
- VBF 1970
- MDWD 2000
- Country
- VBF United States
- MDWD Israel
- Employees
- VBF N/A
- MDWD N/A
- Industry
- VBF Trusts Except Educational Religious and Charitable
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- VBF Finance
- MDWD Health Care
- Exchange
- VBF Nasdaq
- MDWD Nasdaq
- Market Cap
- VBF 177.3M
- MDWD 184.8M
- IPO Year
- VBF N/A
- MDWD 2014
- Fundamental
- Price
- VBF $15.77
- MDWD $19.45
- Analyst Decision
- VBF
- MDWD Strong Buy
- Analyst Count
- VBF 0
- MDWD 1
- Target Price
- VBF N/A
- MDWD $25.00
- AVG Volume (30 Days)
- VBF 45.5K
- MDWD 78.0K
- Earning Date
- VBF 01-01-0001
- MDWD 03-20-2025
- Dividend Yield
- VBF 5.18%
- MDWD N/A
- EPS Growth
- VBF N/A
- MDWD N/A
- EPS
- VBF N/A
- MDWD N/A
- Revenue
- VBF N/A
- MDWD $19,720,000.00
- Revenue This Year
- VBF N/A
- MDWD $10.15
- Revenue Next Year
- VBF N/A
- MDWD $25.62
- P/E Ratio
- VBF N/A
- MDWD N/A
- Revenue Growth
- VBF N/A
- MDWD N/A
- 52 Week Low
- VBF $13.68
- MDWD $11.04
- 52 Week High
- VBF $16.27
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- VBF 54.21
- MDWD 55.03
- Support Level
- VBF $15.44
- MDWD $19.59
- Resistance Level
- VBF $15.98
- MDWD $20.62
- Average True Range (ATR)
- VBF 0.21
- MDWD 0.83
- MACD
- VBF 0.05
- MDWD 0.02
- Stochastic Oscillator
- VBF 59.76
- MDWD 54.60
About VBF Invesco Bond Fund
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.